Genomic convergence and network analysis approach to identify candidate genes in Alzheimer's disease

BMC Genomics

Volumn 15, Issue 1, 2014, Pages

  Talwar, Puneet ^a   Silla, Yumnam ^a   Grover, Sandeep ^a   Gupta, Meenal ^a   Agarwal, Rachna ^b   Kushwaha, Suman ^b   Kukreti, Ritushree ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b INSTITUTE OF HUMAN BEHAVIOUR AND ALLIED SCIENCES   (India)

Author keywords

Clustering; Functional annotation; Gene prioritization; Protein protein interaction

Indexed keywords

ABC TRANSPORTER A1; AMPHIPHYSIN; APOLIPOPROTEIN E; BETA ACTIN; CALCIUM ION; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEOME;

ACTB GENE; ALZHEIMER DISEASE; ARTICLE; CALCIUM SIGNALING; CONTROLLED STUDY; EGFR GENE; ENDOCYTOSIS; ENZYME ACTIVITY; GENE CLUSTER; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC IDENTIFICATION; GENETIC RISK; LINKAGE ANALYSIS; NERVOUS SYSTEM DEVELOPMENT; PROTEIN PROTEIN INTERACTION; SYSTEMS BIOLOGY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; GENETIC LINKAGE; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; MOLECULAR SEQUENCE ANNOTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN INTERACTION MAPPING; PROTEIN INTERACTION MAPS; REPRODUCIBILITY OF RESULTS;

EID: 84899053934     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-15-199     Document Type: Article

References (147)

1. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 2010, 19(R1):R12-R20. 10.1093/hmg/ddq160, 2875049, 20413653.
2. Ghebranious N, Mukesh B, Giampietro PF, Glurich I, Mickel SF, Waring SC, McCarty CA. A pilot study of gene/gene and gene/environment interactions in Alzheimer disease. Clin Med Res 2011, 9(1):17-25. 10.3121/cmr.2010.894, 3064752, 20682755.
3. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2(8). doi:10.1101/cshperspect.a006239.
4. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006, 63(2):168-174. 10.1001/archpsyc.63.2.168, 16461860.
5. Pedersen NL, Posner SF, Gatz M. Multiple-threshold models for genetic influences on age of onset for Alzheimer disease: findings in Swedish twins. Am J Med Genet 2001, 105(8):724-728. 10.1002/ajmg.1608, 11803520.
6. Ertekin-Taner N. Genetics of Alzheimer's disease: a centennial review. Neurol Clin 2007, 25(3):611-667. v, 10.1016/j.ncl.2007.03.009, 2735049, 17659183.
7. Guerreiro RJ, Gustafson DR, Hardy J. The genetic architecture of Alzheimer's disease: beyond APP. PSENs and APOE. Neurobiol Aging 2012, 33(3):437-456.
8. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007, 39(1):17-23. 10.1038/ng1934, 17192785.
9. Wang X, Michaelis ML, Michaelis EK. Functional genomics of brain aging and Alzheimer's disease: focus on selective neuronal vulnerability. Curr Genomics 2010, 11(8):618-633. 10.2174/138920210793360943, 3078686, 21629439.
10. Reddy PH, McWeeney S. Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. Neurobiol Aging 2006, 27(8):1060-1077. 10.1016/j.neurobiolaging.2005.04.014, 16157420.
11. Tsapakis EM, Basu A, Aitchison KJ. Transcriptomics and proteomics: advancing the understanding of psychiatric pharmacogenomics. Clinical Neuropsychiatry 2004, 1(2):117-124.
12. Hallock P, Thomas MA. Integrating the Alzheimer's disease proteome and transcriptome: a comprehensive network model of a complex disease. OMICS 2012, 16(1-2):37-49. 3275800, 22321014.
13. Raj T, Shulman JM, Keenan BT, Chibnik LB, Evans DA, Bennett DA, Stranger BE, De Jager PL. Alzheimer disease susceptibility loci: evidence for a protein network under natural selection. Am J Hum Genet 2012, 90(4):720-726. 10.1016/j.ajhg.2012.02.022, 3322230, 22482808.
14. Jia P, Ewers JM, Zhao Z. Prioritization of epilepsy associated candidate genes by convergent analysis. PLoS One 2011, 6(2):e17162. 10.1371/journal.pone.0017162, 3044734, 21390307.
15. Jain P, Vig S, Datta M, Jindel D, Mathur AK, Mathur SK, Sharma A. Systems biology approach reveals genome to phenome correlation in type 2 diabetes. PLoS One 2013, 8(1):e53522. 10.1371/journal.pone.0053522, 3538588, 23308243.
16. Sharma A, Chavali S, Tabassum R, Tandon N, Bharadwaj D. Gene prioritization in Type 2 Diabetes using domain interactions and network analysis. BMC Genomics 2010, 11:84. 10.1186/1471-2164-11-84, 2824729, 20122255.
17. Gorlov IP, Gallick GE, Gorlova OY, Amos C, Logothetis CJ. GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One 2009, 4(8):e6511. 10.1371/journal.pone.0006511, 2714961, 19652704.
18. Jia P, Kao CF, Kuo PH, Zhao Z. A comprehensive network and pathway analysis of candidate genes in major depressive disorder. BMC Syst Biol 2011, 5(3):S12.
19. Sun J, Jia P, Fanous AH, Webb BT, van den Oord EJ, Chen X, Bukszar J, Kendler KS, Zhao Z. A multi-dimensional evidence-based candidate gene prioritization approach for complex diseases-schizophrenia as a case. Bioinformatics 2009, 25(19):2595-6602. 10.1093/bioinformatics/btp428, 2752609, 19602527.
20. Maver A, Peterlin B. Positional integratomic approach in identification of genomic candidate regions for Parkinson's disease. Bioinformatics 2011, 27(14):1971-1978. 10.1093/bioinformatics/btr313, 21596793.
21. Wang X, Gulbahce N, Yu H. Network-based methods for human disease gene prediction. Brief Funct Genomics 2011, 10(5):280-293. 10.1093/bfgp/elr024, 21764832.
22. Bakir-Gungor B, Sezerman OU. A new methodology to associate SNPs with human diseases according to their pathway related context. PLoS One 2011, 6(10):e26277. 10.1371/journal.pone.0026277, 3201947, 22046267.
23. Liang D, Han G, Feng X, Sun J, Duan Y, Lei H. Concerted perturbation observed in a hub network in Alzheimer's disease. PLoS One 2012, 7(7):e40498. 10.1371/journal.pone.0040498, 3398025, 22815752.
24. Regan K, Wang K, Doughty E, Li H, Li J, Lee Y, Kann MG, Lussier YA. Translating Mendelian and complex inheritance of Alzheimer's disease genes for predicting unique personal genome variants. J Am Med Inform Assoc 2012, 19(2):306-316. 10.1136/amiajnl-2011-000656, 3277633, 22319180.
25. Liu ZP, Wang Y, Zhang XS, Chen L. Identifying dysfunctional crosstalk of pathways in various regions of Alzheimer's disease brains. BMC Syst Biol 2010, 4:S11. 10.1186/1752-0509-4-S2-S11, 2982685, 20840725.
26. Liu ZP, Wang Y, Zhang XS, Xia W, Chen L. Detecting and analyzing differentially activated pathways in brain regions of Alzheimer's disease patients. Mol Biosyst 2011, 7(5):1441-1452. 10.1039/c0mb00325e, 21336338.
27. Goni J, Esteban FJ, de Mendizabal NV, Sepulcre J, Ardanza-Trevijano S, Agirrezabal I, Villoslada P. A computational analysis of protein-protein interaction networks in neurodegenerative diseases. BMC Syst Biol 2008, 2:52. 10.1186/1752-0509-2-52, 2443111, 18570646.
28. Liu Y, Patel S, Nibbe R, Maxwell S, Chowdhury SA, Koyuturk M, Zhu X, Larkin EK, Buxbaum SG, Punjabi NM, Gharib SA, Redline S, Chance MR. Systems biology analyses of gene expression and genome wide association study data in obstructive sleep apnea. Pac Symp Biocomput 2011, 14-25.
29. Zhu W, Yang L, Du Z. Layered functional network analysis of gene expression in human heart failure. PLoS One 2009, 4(7):e6288. 10.1371/journal.pone.0006288, 2712681, 19629191.
30. Sun J, Zhao Z. A comparative study of cancer proteins in the human protein-protein interaction network. BMC Genomics 2010, 11(3):S5.
31. Muhlberger I, Moenks K, Bernthaler A, Jandrasits C, Mayer B, Mayer G, Oberbauer R, Perco P. Integrative bioinformatics analysis of proteins associated with the cardiorenal syndrome. Int J Nephrol 2010, 2011:809378. 3003974, 21188212.
32. Butler AW, Ng MY, Hamshere ML, Forabosco P, Wroe R, Al-Chalabi A, Lewis CM, Powell JF. Meta-analysis of linkage studies for Alzheimer's disease-a web resource. Neurobiol Aging 2009, 30(7):1037-1047. 10.1016/j.neurobiolaging.2009.03.013, 19362756.
33. Hamshere ML, Holmans PA, Avramopoulos D, Bassett SS, Blacker D, Bertram L, Wiener H, Rochberg N, Tanzi RE, Myers A, Wavrant-De Vrièze F, Go R, Fallin D, Lovestone S, Hardy J, Goate A, O'Donovan M, Williams J, Owen MJ. Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's disease. Hum Mol Genet 2007, 16(22):2703-2712. 10.1093/hmg/ddm224, 17725986.
34. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, Jun G, Destefano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013, 45(12):1452-1458. 10.1038/ng.2802, 24162737.
35. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Ramsey K, Caselli RJ, Kukull WA, McKeel D, Morris JC, Hulette CM, Schmechel D, Reiman EM, Rogers J, Stephan DA. Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology. Neurobiol Aging 2010, 31(4):549-566. 10.1016/j.neurobiolaging.2008.05.013, 2844804, 18572275.
36. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Ramsey K, Caselli RJ, Kukull WA, McKeel D, Morris JC, Hulette CM, Schmechel D, Reiman EM, Rogers J, Stephan DA. Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics 2008, 33(2):240-256. 10.1152/physiolgenomics.00242.2007, 2826117, 18270320.
37. Morris JH, Apeltsin L, Newman AM, Baumbach J, Wittkop T, Su G, Bader GD, Ferrin TE. clusterMaker: a multi-algorithm clustering plugin for Cytoscape. BMC Bioinformatics 2011, 12:436. 10.1186/1471-2105-12-436, 3262844, 22070249.
38. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4(1):44-57.
39. da Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009, 37(1):1-13. 10.1093/nar/gkn923, 2615629, 19033363.
40. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The human genome browser at UCSC. Genome Res 2002, 12(6):996-1006. 10.1101/gr.229102. Article published online before print in May 2002, 186604, 12045153.
41. Kohler S, Bauer S, Horn D, Robinson PN. Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet 2008, 82(4):949-958. 10.1016/j.ajhg.2008.02.013, 2427257, 18371930.
42. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, Dolan ME, Cox NJ. SCAN: SNP and copy number annotation. Bioinformatics 2010, 26(2):259-262. 10.1093/bioinformatics/btp644, 2852202, 19933162.
43. Saccone SF, Bolze R, Thomas P, Quan J, Mehta G, Deelman E, Tischfield JA, Rice JP. SPOT: a web-based tool for using biological databases to prioritize SNPs after a genome-wide association study. Nucleic Acids Res 2010, 38(Web Server issue):W201-209. 2896195, 20529875.
44. Boada M, Antunez C, Ramirez-Lorca R, Destefano AL, Gonzalez-Perez A, Gayan J, Lopez-Arrieta J, Ikram MA, Hernandez I, Marin J, Galán JJ, Bis JC, Mauleón A, Rosende-Roca M, Moreno-Rey C, Gudnasson V, Morón FJ, Velasco J, Carrasco JM, Alegret M, Espinosa A, Vinyes G, Lafuente A, Vargas L, Fitzpatrick AL, Launer LJ, Sáez ME, Vázquez E, Becker JT, for the Alzheimer's Disease Neuroimaging Initiative ATP5H/KCTD2 locus is associated with Alzheimer's disease risk. Mol Psychiatry 2013, doi:10.1038/mp.2013.86, for the Alzheimer's Disease Neuroimaging Initiative.
45. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res 2013, 41(Database issue):D991-995. 3531084, 23193258.
46. Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, Holmans P, Rohrer K, Zhao A, Marlowe L, Kaleem M, McCorquodale DS, Cuello C, Leung D, Bryden L, Nath P, Zismann VL, Joshipura K, Huentelman MJ, Hu-Lince D, Coon KD, Craig DW, Pearson JV, Heward CB, Reiman EM, Stephan D, Hardy J, Myers AJ, NACC-Neuropathology Group Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet 2009, 84(4):445-58. 10.1016/j.ajhg.2009.03.011, 2667989, 19361613, NACC-Neuropathology Group.
47. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13(11):2498-2504. 10.1101/gr.1239303, 403769, 14597658.
48. Hernandez-Toro J, Prieto C, De las Rivas J. APID2NET: unified interactome graphic analyzer. Bioinformatics 2007, 23(18):2495-2497. 10.1093/bioinformatics/btm373, 17644818.
49. Barsky A, Gardy JL, Hancock RE, Munzner T. Cerebral: a Cytoscape plugin for layout of and interaction with biological networks using subcellular localization annotation. Bioinformatics 2007, 23(8):1040-1042. 10.1093/bioinformatics/btm057, 17309895.
50. Van Dongen S. Graph clustering by flow simulation. PhD Thesis 2000, The Netherlands: University of Utrecht.
51. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003, 348(14):1356-1364. 10.1056/NEJM2003ra020003, 12672864.
52. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003, 26:81-104. 10.1146/annurev.neuro.26.043002.094919, 12574495.
53. Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle JC, et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet 2012, 8(3):e1002548. 10.1371/journal.pgen.1002548, 3305333, 22438815.
54. Rosenberger A, Sharma M, Muller-Myhsok B, Gasser T, Bickeboller H. Meta analysis of whole-genome linkage scans with data uncertainty: an application to Parkinson's disease. BMC Genet 2007, 8:44. 1940020, 17605797.
55. Tryka KA, Hao L, Sturcke A, Jin Y, Wang ZY, Ziyabari L, Lee M, Popova N, Sharopova N, Kimura M, Feolo M. NCBI's Database of Genotypes and Phenotypes: dbGaP. Nucleic Acids Res 2013, .
56. Fung HC, Scholz S, Matarin M, Simon-Sanchez J, Hernandez D, Britton A, Gibbs JR, Langefeld C, Stiegert ML, Schymick J, Okun MS, Mandel RJ, Fernandez HH, Foote KD, Rodríguez RL, Peckham E, De Vrieze FW, Gwinn-Hardy K, Hardy JA, Singleton A. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 2006, 5(11):911-916. 10.1016/S1474-4422(06)70578-6, 17052657.
57. Simon-Sanchez J, Scholz S, Fung HC, Matarin M, Hernandez D, Gibbs JR, Britton A, de Vrieze FW, Peckham E, Gwinn-Hardy K, Crawley A, Keen JC, Nash J, Borgaonkar D, Hardy J, Singleton A. Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet 2007, 16(1):1-14.
58. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Krüger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009, 41(12):1308-1312. 10.1038/ng.487, 2787725, 19915575.
59. Zhang Y, James M, Middleton FA, Davis RL. Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet B Neuropsychiatr Genet 2005, 137B(1):5-16. 10.1002/ajmg.b.30195, 15965975.
60. Bras J, Guerreiro R, Hardy J. Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease. Nat Rev Neurosci 2012, 13(7):453-464.
61. Smith AV. Genetic analysis: moving between linkage and association. Cold Spring Harb Protoc 2012, 2012(2):174-182.
62. Dorval V, Smith PY, Delay C, Calvo E, Planel E, Zommer N, Buee L, Hebert SS. Gene network and pathway analysis of mice with conditional ablation of Dicer in post-mitotic neurons. PLoS One 2012, 7(8):e44060. 10.1371/journal.pone.0044060, 3428293, 22952873.
63. Hudson NJ, Dalrymple BP, Reverter A. Beyond differential expression: the quest for causal mutations and effector molecules. BMC Genomics 2012, 13:356. 10.1186/1471-2164-13-356, 3444927, 22849396.
64. Boehnke M. Limits of resolution of genetic linkage studies: implications for the positional cloning of human disease genes. Am J Hum Genet 1994, 55(2):379-390. 1918352, 8037215.
65. Ge X, Loh HH, Law PY. mu-Opioid receptor cell surface expression is regulated by its direct interaction with Ribophorin I. Mol Pharmacol 2009, 75(6):1307-1316. 10.1124/mol.108.054064, 2684882, 19289571.
66. Mathieu-Kia AM, Fan LQ, Kreek MJ, Simon EJ, Hiller JM. Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res 2001, 893(1-2):121-134.
67. Teng L, Zhao J, Wang F, Ma L, Pei G. A GPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis. Cell Res 2010, 20(2):138-153. 10.1038/cr.2010.3, 20066010.
68. Saetre P, Jazin E, Emilsson L. Age-related changes in gene expression are accelerated in Alzheimer's disease. Synapse 2011, 65(9):971-974. 10.1002/syn.20933, 21425351.
69. Muma NA, Mariyappa R, Williams K, Lee JM. Differences in regional and subcellular localization of G(q/11) and RGS4 protein levels in Alzheimer's disease: correlation with muscarinic M1 receptor binding parameters. Synapse 2003, 47(1):58-65. 10.1002/syn.10153, 12422374.
70. Bradley SV, Holland EC, Liu GY, Thomas D, Hyun TS, Ross TS. Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. Cancer Res 2007, 67(8):3609-3615. 10.1158/0008-5472.CAN-06-4803, 17440072.
71. Walter S, Atzmon G, Demerath EW, Garcia ME, Kaplan RC, Kumari M, Lunetta KL, Milaneschi Y, Tanaka T, Tranah GJ, Völker U, Yu L, Arnold A, Benjamin EJ, Biffar R, Buchman AS, Boerwinkle E, Couper D, De Jager PL, Evans DA, Harris TB, Hoffmann W, Hofman A, Karasik D, Kiel DP, Kocher T, Kuningas M, Launer LJ, Lohman KK, Lutsey PL, et al. A genome-wide association study of aging. Neurobiol Aging 2011, 32(11):2109. e15-28.
72. Mills IG, Gaughan L, Robson C, Ross T, McCracken S, Kelly J, Neal DE. Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. J Cell Biol 2005, 170(2):191-200. 10.1083/jcb.200503106, 2171420, 16027218.
73. Menegon A, Burgaya F, Baudot P, Dunlap DD, Girault JA, Valtorta F. FAK + and PYK2/CAKbeta, two related tyrosine kinases highly expressed in the central nervous system: similarities and differences in the expression pattern. Eur J Neurosci 1999, 11(11):3777-3788. 10.1046/j.1460-9568.1999.00798.x, 10583467.
74. Combs CK, Johnson DE, Cannady SB, Lehman TM, Landreth GE. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins. J Neurosci 1999, 19(3):928-939.
75. Huang Y, Lu W, Ali DW, Pelkey KA, Pitcher GM, Lu YM, Aoto H, Roder JC, Sasaki T, Salter MW, MacDonald JF. CAKbeta/Pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus. Neuron 2001, 29(2):485-496. 10.1016/S0896-6273(01)00220-3, 11239437.
76. Park SY, Avraham H, Avraham S. Characterization of the tyrosine kinases RAFTK/Pyk2 and FAK in nerve growth factor-induced neuronal differentiation. J Biol Chem 2000, 275(26):19768-19777. 10.1074/jbc.M909932199, 10764815.
77. Siciliano JC, Toutant M, Derkinderen P, Sasaki T, Girault JA. Differential regulation of proline-rich tyrosine kinase 2/cell adhesion kinase beta (PYK2/CAKbeta) and pp 125(FAK) by glutamate and depolarization in rat hippocampus. J Biol Chem 1996, 271(46):28942-28946. 10.1074/jbc.271.46.28942, 8910543.
78. Cotman CW, Anderson AJ. A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol 1995, 10(1):19-45. 10.1007/BF02740836, 7598831.
79. Tian D, Litvak V, Lev S. Cerebral ischemia and seizures induce tyrosine phosphorylation of PYK2 in neurons and microglial cells. J Neurosci 2000, 20(17):6478-6487.
80. Pilon M, Peng XR, Spence AM, Plasterk RH, Dosch HM. The diabetes autoantigen ICA69 and its Caenorhabditis elegans homologue, ric-19, are conserved regulators of neuroendocrine secretion. Mol Biol Cell 2000, 11(10):3277-3288. 10.1091/mbc.11.10.3277, 14991, 11029035.
81. Cao M, Xu J, Shen C, Kam C, Huganir RL, Xia J. PICK1-ICA69 heteromeric BAR domain complex regulates synaptic targeting and surface expression of AMPA receptors. J Neurosci 2007, 27(47):12945-12956. 10.1523/JNEUROSCI.2040-07.2007, 18032668.
82. Spitzenberger F, Pietropaolo S, Verkade P, Habermann B, Lacas-Gervais S, Mziaut H, Pietropaolo M, Solimena M. Islet cell autoantigen of 69 kDa is an arfaptin-related protein associated with the Golgi complex of insulinoma INS-1 cells. J Biol Chem 2003, 278(28):26166-26173. 10.1074/jbc.M213222200, 12682071.
83. Wu Y, Matsui H, Tomizawa K. Amphiphysin I and regulation of synaptic vesicle endocytosis. Acta Med Okayama 2009, 63(6):305-323.
84. Di Paolo G, Sankaranarayanan S, Wenk MR, Daniell L, Perucco E, Caldarone BJ, Flavell R, Picciotto MR, Ryan TA, Cremona O, De Camilli P. Decreased synaptic vesicle recycling efficiency and cognitive deficits in amphiphysin 1 knockout mice. Neuron 2002, 33(5):789-804. 10.1016/S0896-6273(02)00601-3, 11879655.
85. De Jesus-Cortes HJ, Nogueras-Ortiz CJ, Gearing M, Arnold SE, Vega IE. Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration. Neuroreport 2012, 23(16):942-946. 10.1097/WNR.0b013e32835982ce, 3696496, 22975846.
86. Kelly BL, Ferreira A. Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons. Neuroscience 2007, 147(1):60-70. 10.1016/j.neuroscience.2007.03.047, 1993833, 17499934.
87. Wang L, Chiang HC, Wu W, Liang B, Xie Z, Yao X, Ma W, Du S, Zhong Y. Epidermal growth factor receptor is a preferred target for treating amyloid-beta-induced memory loss. Proc Natl Acad Sci U S A 2012, 109(41):16743-16748. 10.1073/pnas.1208011109, 3478595, 23019586.
88. Zhang YW, Wang R, Liu Q, Zhang H, Liao FF, Xu H. Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci U S A 2007, 104(25):10613-10618. 10.1073/pnas.0703903104, 1888796, 17556541.
89. Repetto E, Yoon IS, Zheng H, Kang DE. Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. J Biol Chem 2007, 282(43):31504-31516. 10.1074/jbc.M704273200, 17716970.
90. Conejero-Goldberg C, Hyde TM, Chen S, Dreses-Werringloer U, Herman MM, Kleinman JE, Davies P, Goldberg TE. Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype. Mol Psychiatry 2011, 16(8):836-847. 10.1038/mp.2010.57, 2953572, 20479757.
91. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V. Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus. Brain Res 2010, 1318:167-177. 2826590, 20079340.
92. Elali A, Rivest S. The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease. Front Physiol 2013, 4:45. 3595512, 23494712.
93. Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE. Evidence for impaired amyloid beta clearance in Alzheimer's disease. Alzheimers Res Ther 2013, 5(4):33. 10.1186/alzrt187, 23849219.
94. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008, 118(2):671-682. 2200302, 18202749.
95. Fitz NF, Cronican AA, Saleem M, Fauq AH, Chapman R, Lefterov I, Koldamova R. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. J Neurosci 2012, 32(38):13125-13136. 10.1523/JNEUROSCI.1937-12.2012, 3646580,3646580, 22993429.
96. Malik B, Fernandes C, Killick R, Wroe R, Usardi A, Williamson R, Kellie S, Anderton BH, Reynolds CH. Oligomeric amyloid-beta peptide affects the expression of genes involved in steroid and lipid metabolism in primary neurons. Neurochem Int 2012, 61(3):321-333. 10.1016/j.neuint.2012.05.006, 22579571.
97. Canepa E, Borghi R, Vina J, Traverso N, Gambini J, Domenicotti C, Marinari UM, Poli G, Pronzato MA, Ricciarelli R. Cholesterol and amyloid-beta: evidence for a cross-talk between astrocytes and neuronal cells. J Alzheimers Dis 2011, 25(4):645-653.
98. Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S, Chan J, Fan J, Collins J, Wellington CL. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem 2010, 285(44):34144-34154. 10.1074/jbc.M110.108100, 2962513, 20739291.
99. Fan J, Donkin J, Wellington C. Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E. Biofactors 2009, 35(3):239-248. 10.1002/biof.37, 19472365.
100. Koldamova R, Fitz NF, Lefterov I. The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration. Biochim Biophys Acta 2010, 1801(8):824-830. 10.1016/j.bbalip.2010.02.010, 3712769, 20188211.
101. Wang XF, Cao YW, Feng ZZ, Fu D, Ma YS, Zhang F, Jiang XX, Shao YC. Quantitative assessment of the effect of ABCA1 gene polymorphism on the risk of Alzheimer's disease. Mol Biol Rep 2013, 40(2):779-785. 10.1007/s11033-012-2115-9, 23111454.
102. Lupton MK, Proitsi P, Lin K, Hamilton G, Daniilidou M, Tsolaki M, Powell JF. The Role of ABCA1 Gene Sequence Variants on Risk of Alzheimer's Disease. J Alzheimers Dis 2014, 38(4):897-906.
103. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 2002, 23(5):655-664. 10.1016/S0197-4580(01)00340-2, 12392766.
104. Ricciarelli R, d'Abramo C, Massone S, Marinari U, Pronzato M, Tabaton M. Microarray analysis in Alzheimer's disease and normal aging. IUBMB Life 2004, 56(6):349-354. 10.1080/15216540412331286002, 15370883.
105. Leduc V, Legault V, Dea D, Poirier J. Normalization of gene expression using SYBR green qPCR: a case for paraoxonase 1 and 2 in Alzheimer's disease brains. J Neurosci Methods 2011, 200(1):14-19. 10.1016/j.jneumeth.2011.05.026, 21672555.
106. Maloney MT, Minamide LS, Kinley AW, Boyle JA, Bamburg JR. Beta-secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid beta: a feedforward mechanism for Alzheimer's disease. J Neurosci 2005, 25(49):11313-11321. 10.1523/JNEUROSCI.3711-05.2005, 16339026.
107. Bamburg JR, Bloom GS. Cytoskeletal pathologies of Alzheimer disease. Cell Motil Cytoskeleton 2009, 66(8):635-649. 10.1002/cm.20388, 2754410, 19479823.
108. Yao J, Khan AN. Involvement of Actin Pathology in Alzheimer's disease. Cell Dev Biol 2013, 2:e121. doi:10.4172/2168-9296.1000e121.
109. Tell V, Holzer M, Herrmann L, Mahmoud KA, Schächtele C, Totzke F, Hilgeroth A. Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases. Bioorg Med Chem Lett 2012, 22(22):6914-8. 10.1016/j.bmcl.2012.09.006, 23039927.
110. Chang KH, Vincent F, Shah K. Deregulated Cdk5 triggers aberrant activation of cell cycle kinases and phosphatases inducing neuronal death. J Cell Sci 2012, 125(Pt 21):5124-5137.
111. Cui JG, Li YY, Zhao Y, Bhattacharjee S, Lukiw WJ. Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease. J Biol Chem 2010, 285(50):38951-38960. 10.1074/jbc.M110.178848, 2998119, 20937840.
112. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H, Alzheimer's Disease Neuroimaging Initiative Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 2012, 79(9):897-905. 10.1212/WNL.0b013e318266fa70, 3425844, 22855860, Alzheimer's Disease Neuroimaging Initiative.
113. Song F, Poljak A, Crawford J, Kochan NA, Wen W, Cameron B, Lux O, Brodaty H, Mather K, Smythe GA, Sachdev PS. Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS One 2012, 7(6):e34078. 10.1371/journal.pone.0034078, 3372509, 22701550.
114. Vuletic S, Li G, Peskind ER, Kennedy H, Marcovina SM, Leverenz JB, Petrie EC, Lee VM, Galasko D, Schellenberg GD, Albers JJ. Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid. J Alzheimers Dis 2008, 15(3):409-417. 2667787, 18997294.
115. Fukuyama R, Mizuno T, Mori S, Yanagisawa K, Nakajima K, Fushiki S. Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease. Eur Neurol 2000, 43(3):161-169. 10.1159/000008157, 10765057.
116. Hesse C, Larsson H, Fredman P, Minthon L, Andreasen N, Davidsson P, Blennow K. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res 2000, 25(4):511-517. 10.1023/A:1007516210548, 10823584.
117. Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, Bertelsen S, Hinrichs A, Fagan AM, Holtzman DM Morris JC, Goate AM. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum Mol Genet 2012, 21(20):4558-4571. 10.1093/hmg/dds296, 3459471, 22821396.
118. Skoog I, Hesse C, Fredman P, Andreasson LA, Palmertz B, Blennow K. Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions. Arch Neurol 1997, 54(3):267-272. 10.1001/archneur.1997.00550150029012, 9074395.
119. Merched A, Blain H, Visvikis S, Herbeth B, Jeandel C, Siest G. Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. J Neurol Sci 1997, 145(1):33-39. 10.1016/S0022-510X(96)00234-1, 9073026.
120. Lindh M, Blomberg M, Jensen M, Basun H, Lannfelt L, Engvall B, Scharnagel H, Marz W, Wahlund LO, Cowburn RF. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci Lett 1997, 229(2):85-88. 10.1016/S0304-3940(97)00429-1, 9223597.
121. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarker and Lifestyle Research Group Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 2012, 69(10):1318-1325. 10.1001/archneurol.2012.1282, 22801742, Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarker and Lifestyle Research Group.
122. Moskvina V, Harold D, Russo G, Vedernikov A, Sharma M, Saad M, Holmans P, Bras JM, Bettella F, Keller MF, Nicolaou N, Simón-Sánchez J, Gibbs JR, Schulte C, Durr A, Guerreiro R, Hernandez D, Brice A, Stefánsson H, Majamaa K, Gasser T, Heutink P, Wood N, Martinez M, Singleton AB, Nalls MA, Hardy J, Owen MJ, O'Donovan MC, Williams J, et al. Analysis of Genome-Wide Association Studies of Alzheimer Disease and of Parkinson Disease to Determine If These 2 Diseases Share a Common Genetic Risk. JAMA Neurol 2013, 70(10):1268-76.
123. Marder K, Tang MX, Alfaro B, Mejia H, Cote L, Louis E, Stern Y, Mayeux R. Risk of Alzheimer's disease in relatives of Parkinson's disease patients with and without dementia. Neurology 1999, 52(4):719-724. 10.1212/WNL.52.4.719, 10078716.
124. Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, Harris J, Waters C, Ford B, Frucht S, Fahn S, Ottman R, Marder K. Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol 2004, 61(7):1033-1039.
125. Rocca WA, Bower JH, Ahlskog JE, Elbaz A, Grossardt BR, McDonnell SK, Schaid DJ, Maraganore DM. Risk of cognitive impairment or dementia in relatives of patients with Parkinson disease. Arch Neurol 2007, 64(10):1458-1464. 10.1001/archneur.64.10.1458, 17923629.
126. Hart GT, Ramani AK, Marcotte EM. How complete are current yeast and human protein-interaction networks?. Genome Biol 2006, 7(11):120. 10.1186/gb-2006-7-11-120, 1794583, 17147767.
127. Moreau Y, Tranchevent LC. Computational tools for prioritizing candidate genes: boosting disease gene discovery. Nat Rev Genet 2012, 13(8):523-536. 10.1038/nrg3253, 22751426.
128. Bornigen D, Tranchevent LC, Bonachela-Capdevila F, Devriendt K, De Moor B, De Causmaecker P, Moreau Y. An unbiased evaluation of gene prioritization tools. Bioinformatics 2012, 28(23):3081-3088. 10.1093/bioinformatics/bts581, 23047555.
129. Antunez C, Boada M, Gonzalez-Perez A, Gayan J, Ramirez-Lorca R, Marin J, Hernandez I, Moreno-Rey C, Moron FJ, Lopez-Arrieta J, Mauleón A, Rosende-Roca M, Noguera-Perea F, Legaz-García A, Vivancos-Moreau L, Velasco J, Carrasco JM, Alegret M, Antequera-Torres M, Manzanares S, Romo A, Blanca I, Ruiz S, Espinosa A, Castaño S, García B, Martínez-Herrada B, Vinyes G, Lafuente A, Becker JT, et al. The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer's disease. Genome Med 2011, 3(5):33. 10.1186/gm249, 3219074, 21627779.
130. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon KD, Liang WS, Herbert RH, Beach T, Rohrer KC, Zhao AS, Leung D, Bryden L, Marlowe L, Kaleem M, Mastroeni D, Grover A, Heward CB, Ravid R, Rogers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007, 54(5):713-720. 10.1016/j.neuron.2007.05.022, 2587162, 17553421.
131. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 2005, 1(1):55-66. 10.1016/j.jalz.2005.06.003, 1864941, 17476317.
132. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 2008, 65(1):45-53.
133. Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R, Lee JH, Bird TD, Bennett DA, Diaz-Arrastia R, Goate AM, Farlow M, Ghetti B, Sweet RA, Foroud TM, Mayeux R, NIA-LOAD/NCRAD Family Study Group Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet 2011, 7(2):e1001308. 10.1371/journal.pgen.1001308, 3040659, 21379329, NIA-LOAD/NCRAD Family Study Group.
134. Hu X, Pickering E, Liu YC, Hall S, Fournier H, Katz E, Dechairo B, John S, Van Eerdewegh P, Soares H, Alzheimer's Disease Neuroimaging Initiative Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease. PLoS One 2011, 6(2):e16616. 10.1371/journal.pone.0016616, 3044719, 21390209, Alzheimer's Disease Neuroimaging Initiative.
135. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009, 41(10):1088-1093. 10.1038/ng.440, 2845877, 19734902.
136. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002, 30(17):3894-3900. 10.1093/nar/gkf493, 137415, 12202775.
137. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010, 7(4):248-249. 10.1038/nmeth0410-248, 2855889, 20354512.
138. Loots G, Ovcharenko I. ECRbase: database of evolutionary conserved regions, promoters, and transcription factor binding sites in vertebrate genomes. Bioinformatics 2007, 23(1):122-124. 10.1093/bioinformatics/btl546, 17090579.
139. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, Zeng C, Gao Y, Hu H, Hu W, Li C, Lin W, Liu S, Pan H, Tang X, Wang J, Wang W, Yu J, Zhang B, Zhang Q, , et al. International HapMap Consortium A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449(7164):851-861. 10.1038/nature06258, 2689609, 17943122, International HapMap Consortium.
140. Gray KA, Daugherty LC, Gordon SM, Seal RL, Wright MW, Bruford EA. Genenames.org: the HGNC resources in 2013. Nucleic Acids Res 2013, 41(Database issue):D545-552. 3531211, 23161694.
141. Silla Y, Sundaramoorthy E, Talwar P, Sengupta S. S-linked protein homocysteinylation: identifying targets based on structural, physicochemical and protein-protein interactions of homocysteinylated proteins. Amino Acids 2013, 44(5):1307-1316. 10.1007/s00726-013-1465-5, 23400378.
142. Wu CH, Apweiler R, Bairoch A, Natale DA, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin MJ, Mazumder R, O'Donovan C, Redaschi N, Suzek B. The Universal Protein Resource (UniProt): an expanding universe of protein information. Nucleic Acids Res 2006, 34(Database issue):D187-191. 1347523, 16381842.
143. Assenov Y, Ramirez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics 2008, 24(2):282-284. 10.1093/bioinformatics/btm554, 18006545.
144. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Björling L, Ponten F. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010, 28(12):1248-1250. 10.1038/nbt1210-1248, 21139605.
145. Brohee S, van Helden J. Evaluation of clustering algorithms for protein-protein interaction networks. BMC Bioinformatics 2006, 7:488. 10.1186/1471-2105-7-488, 1637120, 17087821.
146. Li SJ, Peng M, Li H, Liu BS, Wang C, Wu JR, Li YX, Zeng R. Sys-BodyFluid: a systematical database for human body fluid proteome research. Nucleic Acids Res 2009, 37(Database issue):D907-912. 2686600, 18978022.
147. Pirooznia M, Nagarajan V, Deng Y. GeneVenn - A web application for comparing gene lists using Venn diagrams. Bioinformation 2007, 1(10):420-422. 10.6026/97320630001420, 1899164, 17597932.